The Volume Effect and Safety of 6% Hydroxyethyl Starch 130/0.4 in Patients Undergoing
Major Elective Surgery: An Uncontrolled, Open-Labeled, Multi-Center Study
Copyright © 2013 SciRes. OJAnes
337
cation: Pharmacokinetics and Safety after Multiple Infu-
sions of 10% Solution in Healthy Volunteers,” Drugs in R
& D, Vol. 4, No. 3, 2003, pp. 149-157.
doi:10.2165/00126839-200304030-00002
[3] C. Jungheinrich, W. Sauermann, F. Bepperling and N.
Vogt, “Volume Efficacy and Reduced Influence on Meas-
ures of Coagulation Using Hydroxyethyl Starch 130/0.4
(6%) with an Optimised in Vivo Molecular Weight in Or-
thopaedic Surgery: A Randomised, Double-Blind Study,”
Drugs in R & D, Vol. 5, No. 1, 2004, pp. 1-9.
doi:10.2165/00126839-200405010-00001
[4] P. Van Der Linden, M. James, M. Mythen and R. B.
Weiskopf, “Safety of Modern Starches Used during Sur-
gery,” Anesthesia & Analgesia, Vol. 116, No. 1, 2013, pp.
35-48.
[5] G. Godet, J. J. Lehot, G. Janvier, A. Steib, V. De Castro
and P. Coriat, “Safety of HES 130/0.4 (Voluven®) in Pa-
tients with Preoperative Renal Dysfunction Undergoing
Abdominal Aortic Surgery: A Prospective, Randomized,
Controlled, Parallel-Group Multicentre Trial,” European
Journal of Anaesthesiology, Vol. 25, No. 12, 2008, pp.
986-994. doi:10.1017/S026502150800447X
[6] B. E. Ickx, F. Bepperling, C. Melot, C. Schulman and P. J.
Van Der Linden, “Plasma Substitution Effects of a New
Hydroxyethyl Starch HES 130/0.4 Compared with HES
200/0.5 during and after Extended Acute Normovolemic
Haemodilution,” British Journal of Anaesthesia, Vol. 91,
No. 2, 2003, pp. 196-202. doi:10.1093/bja/aeg159
[7] T. Standl, H. Lochbuehler, C. Galli, A. Reich, G. Dietrich
and H. Hagemann, “HES 130/0.4 (Voluven) or Human
Albumin in Children Younger than 2 yr Undergoing Non-
Cardiac Surgery. A Prospective, Randomized, Open Label,
Multicentre Trial,” European Journal of Anaesthesiology,
Vol. 25, No. 6, 2008, pp. 437-445.
doi:10.1017/S0265021508003888
[8] C. Hanart, M. Khalife, A. De Villé, F. Otte, S. De Hert
and P. Van der Linden, “Perioperative Volume Replace-
ment in Children Undergoing Cardiac Surgery: Albumin
versus Hydroxyethyl Starch 130/0.4,” Critical Care Me-
dicine, Vol. 37, No. 2, 2009, pp. 696-701.
doi:10.1097/CCM.0b013e3181958c81
[9] P. Van der Linden, A. De Villé, A. Hofer, M. Heschl and
H. Gombotz, “Six Percent Hydroxyethyl Starch 130/0.4
(Voluven®) versus 5% Human Serum Albumin for Vol-
ume Replacement Therapy during Elective Open-Heart
Surgery in Pediatric Patients,” Anesthesiology, 2013,
Epub Ahead of Print.
[10] T. Gondos, Z. Marjanek, Z. Ulakcsai, Z. Szabó, L. Bogár,
M. Károlyi, B. Gartner, K. Kiss, A. Havas and J. Futó,
“Short-Term Effectiveness of Different Volume Replace-
ment Therapies in Postoperative Hypovolaemic Patients,”
European Journal of Anaesthesiology, Vol. 27, No. 9,
2010, pp. 794-800. doi:10.1097/EJA.0b013e32833b3504
[11] O. Langeron, M. Doelberg, A. Eng-Than, F. Bonnet, X.
Capdevila and P. I. Coriat “Voluven, a Lower Substituted
Novel Hydroxyethyl Starch (HES 130/0.4), Causes Fewer
Effects on Coagulation in Major Orthopedic Surgery than
HES 200/0.5,” Anesthesia & Analgesia, Vol. 92, No. 2,
2001, pp. 855-862.
doi:10.1097/00000539-200104000-00011
[12] S. Gandhi, D. Warltier, R. Weiskopf, R. Koorn, D. Miller,
R. E. Shangraw, D. S. Prough, D. Baus, F. Bepperling and
D. C. Warltier, “Volume Replacement Therapy dur- ing
Major Orthopedic Surgery Using Voluven® (Hydro-
xyethyl Starch 130/0.4) or Hetastarch,” Anesthesiology,
Vol. 106, No. 6, 2007, pp. 1120-1127.
doi:10.1097/01.anes.0000265422.07864.37
[13] N. H. Vogt, U. Bothner, G. Lerch, K. H. Lindner and M.
Georgieff, “Large-Dose Administration of 6% Hydroxye-
thyl Starch 200/0.5 in Total Hip Arthroplasty: Plasma
Homeostasis, Hemostasis, and Renal Function Compared
to Use of 5% Human Albumin,” Anesthesia & Analgesia,
Vol. 83, No. 2, 1996, pp. 262-268.
doi:10.1213/00000539-199608000-00011
[14] P. Van der Linden and B. E. Ickx, “The Effects of Colloid
Solutions on Hemostasis,” Canadian Journal of Anesthe-
sia, Vol. 53, No. 6, 2006, pp. S30-S39.
doi:10.1007/BF03022250
[15] S. A. Kozek-Langenecker, C. Jungheinrich, W. Sauer-
mann and P. Van der Linden, “The Effects of Hydro-
xyethyl Starch 130/0.4 (6%) on Blood Loss and Use of
Blood Products in Major Surgery: A Pooled Analysis of
Randomized Clinical Trials,” Anesthesia & Analgesia,
Vol. 107, No. 2, 2008, pp. 382-390.
doi:10.1213/ane.0b013e31817e6eac
[16] M. F. James, W. L. Michell, I. A. Joubert, A. J. Nicol, P.
H. Navsaria and R. S. Gillespie, “Resuscitation with Hy-
droxyethyl Starch Improves Renal Function and Lactate
Clearance in Penetrating Trauma in a Randomized Con-
trolled Study: The FIRST Trial (Fluids in Resuscitation of
Severe Trauma),” British Journal of Anaesthesia, Vol.
107, No. 5, 2011, pp. 693-702. doi:10.1093/bja/aer229
[17] S. M. Kasper, P. Meinert, S. Kampe, C. Goerg, C. Geisen,
U. Mehlhorn and C. Diefenbach, “Large-Dose Hydro-
xyethyl Starch 130/0.4 Does Not Increase Blood Loss and
Transfusion Requirements in Coronary Artery Bypass
Surgery Compared with Hydroxyethyl Starch 200/0.5 at
Recommended Doses,” Anesthesiology, Vol. 99, No. 1,
2003, pp. 42-47. doi:10.1097/00000542-200307000-00010
[18] B. Ellger, J. Freyhoff, H. van Aken, M. Booke and M. A.
Marcus, “High-Dose Volume Replacement Using HES
130/0.4 during Major Surgery: Impact on Coagulation and
Incidence of Postoperative Itching,” Netherlands Tij-
dschrift Anesthesia, Vol. 19, No. 1, 2006, pp. 63-68.
[19] P. J. Van der Linden, S. G. De Hert, D. Deraedt, S. Crom-
heecke, K. De Decker, R. De Paep, I. Rodrigus, A. Daper
and A. Trenchant, “Hydroxyethyl Starch 130/0.4 versus
Modified Fluid Gelatin for Volume Expansion in Cardiac
Surgery Patients: The Effects on Perioperative Bleeding
and Transfusion Needs,” Anesthesia & Analgesia, Vol.
101, No. 3, 2005, pp. 629-634.
doi:10.1213/01.ANE.0000175216.53374.27
[20] T. A. Neff, M. Doelberg, C. Jungheinrich, A. Sauerland,
D. R. Spahn and R. Stocker, “Repetitive Large-Dose Infu-
sion of the Novel Hydroxyethyl Starch 130/0.4 in Patients
with Severe Head Injury,” Anesthesia & Analgesia, Vol.
96, No. 5, 2003, pp. 1453-1459.
doi:10.1213/01.ANE.0000061582.09963.FD